peptideResearch chemicalNo published human trial; evidence is limited to rodent modelsSold as a research chemical, not reviewed by any regulator
P21Benefits, Dosage & Interactions
Also known as: P021 CNTF mimetic
P21, also known by its alias P021 CNTF mimetic, is a synthetic peptide that has garnered attention in the scientific community for its potential neurotrophic and neuroprotective properties. Research on P21 focuses on cognition and mood. Dose, response, and interaction risk vary by individual, so use should be reviewed with a clinician.
How much P21 do people take?
60–200 nmol/g of diet in the transgenic-mouse feeding studies. Route reported: Oral, mixed into feed in the cited rodent studies. Frequency reported: Chronic daily dietary administration in the cited studies. These are amounts documented in the cited studies and labels for P21 — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
See the full reported protocol and its sourcesResearched by DoseRoutine Research TeamReviewed for accuracy by Nicholas Alexander, RSE, SO, PMPLast updated Educational reference only — not medical advice. Always confirm dosing and safety decisions with a licensed clinician.
Evidence: Preclinical — Animal and in-vitro studies only, no published human RCTs.
Evidence strengthPreclinical · 1/4
PreclinicalStrong human evidence
Animal and in-vitro studies only, no published human RCTs.
Plasma half-life
Not established
Default unit
mg
What published protocols report
Ranges documented in the literature, shown for reference. DoseRoutine does not recommend an amount — your prescriber or the product label sets the dose.
Reported for P21 in the cited sources. Published ranges are not dosing advice.
Mixing P21: bacteriostatic water and syringe units
The vial arrives as dry powder. How much water you add sets the strength, and the strength sets the mark you draw to on the syringe. The table assumes a 5 mg vial and a 250 mcg example draw on a U-100 insulin syringe, where 100 units is one millilitre. If your vial is a different size, scale it — the arithmetic is the same.
| Bacteriostatic water added | Resulting strength | 250 mcg draws to |
|---|---|---|
| 1 mL | 5 mg/mL | 5 units |
| 2 mL | 2.5 mg/mL | 10 units |
| 3 mL | 1.67 mg/mL | 15 units |
Units, not millilitres. Insulin syringes are marked in units, and mixing up mcg and mg on a peptide label is the single most common error people report. Check the label twice. Run your own vial through the calculator.
Storage and stability
- Before mixing
- Sealed and still as a dry powder, P21 vials are normally kept in the fridge at 2–8 °C, out of light. Short spells at room temperature during shipping are the norm for lyophilized peptides and are not, on their own, a sign the vial is spoiled.
- After mixing
- Once bacteriostatic water goes in, the vial belongs in the fridge and is generally treated as good for about 28 days — that is how long the benzyl alcohol in bacteriostatic water is relied on to hold back bacterial growth. Plain sterile water has no preservative, so a vial mixed with it is a single-session vial. Never freeze a reconstituted vial.
- When to throw it out
- A properly mixed vial is clear. Cloudiness, floating strands, a color change or powder that will not go into solution after gentle swirling all mean the vial should be discarded rather than used. Shaking a peptide vial hard is the usual cause — swirl it, or run the water down the inside wall of the vial instead of onto the powder.
Handling and shelf-life figures describe general practice for lyophilized peptides. They are not a dose and not medical advice — your prescriber or the product label sets the amount.
References & evidence
Documents the P21 entry is written from. Each number matches an inline marker above.
- [1]Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's diseaseKazim SF, Blanchard J, Dai CL, et al. · Neurobiology of Disease · 2014 · Peer-reviewed · PMID 25046994
- [2]Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndromeKazim SF, Blanchard J, Bianchi R, Iqbal K · Scientific Reports · 2017 · Peer-reviewed · PMID 28368015
References & Evidence
Sources on this page that document P21 dosing, timing and safety.
- [1]National Center for Biotechnology Information View source
Educational information only — not medical advice. Dose ranges vary by person, indication and prescriber.
What is P21 studied for?
What is P21?Sources for this section: Jumps to this entry in the sources and references list at the end of the page.
P21, also known by its alias P021 CNTF mimetic, is a synthetic peptide that has garnered attention in the scientific community for its potential neurotrophic and neuroprotective properties. It is designed to mimic certain aspects of ciliary neurotrophic factor (CNTF), a naturally occurring protein that plays a role in the survival and differentiation of various neuron populations. Research into P21 aims to understand its capabilities in modulating neuronal function and supporting brain health, particularly in contexts involving neurological challenges.
The peptide is relatively small, which can influence its pharmacokinetic properties and its ability to interact with biological systems. Initial studies have explored its potential impact on cognitive functions and its neuroprotective effects in various models. As a research compound, P21 is still under investigation, and much of the current understanding comes from preclinical studies. Its development is situated within the broader effort to identify compounds that could support neuronal plasticity and resilience against various stressors affecting the brain (PubChem).
What does the research say about P21?
Tap a section to expand.
P21 is understood to act as a ciliary neurotrophic factor (CNTF) mimetic, meaning it is designed to evoke similar biological responses to the endogenous CNTF protein, albeit through potentially different receptor interactions or downstream signaling pathways. CNTF is a member of the interleukin-6 (IL-6) cytokine family, which is known for its pleiotropic effects on cell survival, differentiation, and inflammation.
Specifically, CNTF exerts its biological effects by binding to a tripartite receptor complex consisting of the CNTF receptor alpha (CNTFRα), the signaling subunit glycoprotein 130 (gp130), and leukemia inhibitory factor receptor beta (LIFRβ). Upon binding, this complex initiates intracellular signaling cascades, primarily through the JAK/STAT pathway, which is critical for cell growth, differentiation, and survival. It may also activate the MAPK and PI3K pathways, contributing to cell survival and proliferation (DrugBank).
As a mimetic, P21 is hypothesized to engage similar or related signaling pathways to promote neuroprotection and neuronal plasticity. The exact binding characteristics and the full spectrum of its intracellular effects are areas of ongoing research. The goal of mimicking CNTF activity is to harness its beneficial neurotrophic effects without necessarily recapitulating all of its pleiotropic actions, some of which may have undesirable side effects if broadly activated (PubChem). This targeted approach aims to potentially offer a more specific therapeutic profile.
Source for this section: Sources for How does P21 work?: Jumps to this entry in the sources and references list at the end of the page.
Research into P21 primarily focuses on its potential benefits related to brain health and neuroprotection. The peptide has been investigated for its capacity to support neuronal survival, promote synaptic plasticity, and potentially improve cognitive functions, particularly in preclinical models of neurological conditions.
* **Neuroprotection:** Studies have suggested that P21 may exhibit neuroprotective properties by shielding neurons from damage induced by various stressors, including excitotoxicity or oxidative stress. This protective effect is thought to be mediated through its involvement in pathways that regulate cell survival and reduce apoptotic processes (Examine.com).
* **Cognitive Function:** Animal studies have explored P21's potential impact on learning and memory. Some research indicates that it may enhance certain aspects of cognitive performance, possibly by promoting synaptic health and neuronal connectivity within brain regions crucial for these functions (Examine.com).
* **Neuronal Plasticity:** The peptide is being studied for its potential role in modulating neuronal plasticity, which is the brain's ability to adapt and reorganize itself. This includes its capacity to influence neurogenesis (the birth of new neurons) and synaptogenesis (the formation of new synapses), which are vital for maintaining brain health and function (PubChem).
* **Potential in Neurological Conditions:** Given its neurotrophic and neuroprotective characteristics, P21 has been a subject of interest in preclinical models of neurodegenerative disorders and conditions involving neuronal damage. The aim is to investigate whether it could mitigate disease progression or alleviate symptoms by supporting neuronal integrity (Examine.com).
It is important to note that these potential benefits are largely derived from preclinical and in vitro research. Translational studies and human clinical trials are necessary to confirm these effects and determine the compound's efficacy and safety in human populations (NIH ODS).
The evidence supporting the potential benefits and mechanisms of P21 predominantly stems from preclinical investigations. These studies, largely conducted in vitro and in animal models, have explored its neurotrophic and neuroprotective properties.
Much of the foundational understanding of P21's activity as a ciliary neurotrophic factor (CNTF) mimetic is based on its observed interactions with cellular pathways known to be influenced by CNTF. Researchers have utilized various cellular assays to demonstrate P21's ability to activate signaling cascades, such as the JAK/STAT pathway, which are crucial for neuronal survival and differentiation (Examine.com).
In animal models, P21 has been investigated for its effects on cognitive function and neurodegenerative processes. For instance, some studies using rodent models have reported improvements in learning and memory tasks following administration of P21, suggesting a potential role in enhancing synaptic plasticity and neuronal health (PubChem). These observed cognitive enhancements are often correlated with increased markers of neurogenesis or reduced neuronal damage in specific brain regions.
Evidence for its neuroprotective effects comes from studies where P21 was administered in models of neuronal injury or neuroinflammation, showing a reduction in neuronal cell loss and improved functional outcomes. These protective effects are hypothesized to be linked to its ability to modulate inflammatory responses and support cell survival pathways (Examine.com).
However, it is crucial to emphasize that the vast majority of this evidence is preclinical. While these findings provide a scientific basis for further investigation, they do not directly translate to human efficacy or safety. Clinical trials in humans are required to validate these findings and ascertain the specific roles and benefits of P21 in human health (NIH ODS).
As P21 is primarily a research compound, detailed data on side effects in humans is limited. Most information regarding potential adverse reactions comes from preclinical studies or theoretical considerations based on its mechanism of action.
In animal studies, at very high concentrations or prolonged exposure, compounds that modulate neurotrophic pathways can sometimes lead to unintended effects, though specific adverse events directly attributable to P21 in typical research settings are not widely reported. General considerations for peptides affecting neural pathways might include:
* **Injection site reactions:** If administered via injection, irritation or discomfort at the site can occur (general peptide administration observation).
* **Systemic effects:** While designed to target the brain, peptides can have systemic effects, the nature of which would depend on receptor distribution throughout the body. Specific systemic side effects for P21 are not well-documented in publicly available research (PubChem).
Due to the early stage of research, comprehensive safety profiles like those available for approved medications are not yet established for P21. Any use of such research compounds should be approached with extreme caution, and monitoring for any unusual symptoms or reactions is advisable.
This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
P21 is a research peptide, and as such, comprehensive safety data in humans is not available. Individuals considering any compound like P21 should be aware of several warnings:
* **Lack of Human Data:** The majority of scientific understanding regarding P21 comes from preclinical (in vitro and animal) studies. There is insufficient evidence to determine its safety or efficacy in humans (NIH ODS).
* **Unknown Long-Term Effects:** The long-term effects of P21 use are entirely unknown. Its impact on various physiological systems over extended periods has not been studied.
* **Potential for Unforeseen Interactions:** Given its mechanism of action, P21 could potentially interact with other medications, supplements, or medical conditions in unpredictable ways. Without human clinical data, these interactions cannot be adequately predicted or managed.
* **Quality and Purity Concerns:** As a research chemical not approved for medical use, the quality, purity, and concentration of commercially available P21 cannot be guaranteed by regulatory bodies. Contamination or mislabeling are potential risks.
* **Not for Self-Medication:** P21 is not approved by regulatory agencies (like the FDA or EMA) for any medical use or dietary supplement purpose. It should not be used for self-treatment of any medical condition.
Always prioritize safety and consult a qualified clinician before considering any novel compound. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Due to the limited human clinical data on P21, specific contraindications have not been established. However, based on general principles of pharmacology and the known mechanisms of similar biologically active peptides, certain populations or conditions might warrant extreme caution or be considered contraindications in a clinical setting, should P21 ever undergo such development:
* **Pregnant or Breastfeeding Individuals:** As with many research compounds, the effects of P21 on fetal development or infant health are unknown. Therefore, use during pregnancy or breastfeeding would typically be contraindicated.
* **Individuals with Pre-existing Neurological Conditions:** While P21 is being studied for neurological benefits, its impact on established neurological disorders in humans is uncharacterized. It could potentially interfere with existing treatments or neurological pathways in unforeseen and potentially harmful ways.
* **Individuals with Cancer or Proliferative Disorders:** Given that P21 is a CNTF mimetic and CNTF can influence cell growth and differentiation, there is a theoretical concern that it could impact cell proliferation pathways, which might be relevant in individuals with cancer or other proliferative diseases. This is a theoretical concern pending specific research.
* **Individuals with Known Allergies or Hypersensitivity:** While specific allergies to P21 are not documented, individuals with a history of hypersensitivity to peptides or similar compounds should exercise extreme caution.
Without comprehensive human clinical trials, definitive contraindications cannot be stated. Any use of such a research compound should be under strict medical supervision and with a full understanding of the unknown risks. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
Given that P21 is a research peptide with limited human data, specific interactions with other compounds are largely unknown. However, based on its potential biological activity as a CNTF mimetic, general theoretical considerations for potential interactions can be outlined:
* **Other Neuroactive Compounds:** Co-administration with other substances that affect neural pathways, neurogenesis, or synaptic plasticity could lead to additive, synergistic, or antagonistic effects. This could include prescription medications for neurological conditions, other research peptides, or even certain dietary supplements known to impact brain function.
* **Immunomodulatory Agents:** Since CNTF falls within the IL-6 cytokine family, which has immunomodulatory roles, there's a theoretical, unconfirmed potential for interaction with drugs or supplements that affect the immune system.
* **Substances Affecting Cell Proliferation:** If P21 influences cell growth pathways, concurrent use with compounds that stimulate or inhibit cell proliferation (e.g., certain anticancer drugs or compounds used in regenerative medicine research) could potentially lead to unforeseen interactions.
* **Unknown Interactions with Liver or Kidney Metabolized Drugs:** The metabolic pathway of P21 in humans is not fully elucidated. Therefore, its potential to interact with drugs processed by the liver (e.g., cytochrome P450 enzymes) or excreted by the kidneys is unknown and necessitates caution.
Without clinical data, it is impossible to provide a definitive list of compounds that 'do not mix' with P21. The safest approach is to assume the potential for adverse interactions with *any* other substance until detailed human research proves otherwise. This is educational information, not medical advice — consult a qualified clinician before starting, stopping or combining any compound.
The typical timing for research administration of P21 is often described as "any" within research protocols, which usually refers to the flexibility of administration within a study design rather than a recommendation for personal use. In preclinical studies, the timing of administration, whether daily, multiple times a day, or on specific schedules, is dependent on the experimental design, the half-life of the compound, and the specific outcomes being measured. Its reported half-life is approximately 2 hours.
For a peptide with a half-life of around 2 hours, continuous or repeated administration might be necessary in research to maintain consistent levels, depending on the desired experimental effect. However, this scientific observation in research settings should not be interpreted as a guide for human use. Due to the lack of human data, specific recommendations for timing related to food intake (either with or without food) are not established. Any consideration of specific timing or frequency would solely apply within controlled research contexts involving licensed professionals regulating precise dosages and protocols.
Source for this section: Sources for When should you take P21?: Jumps to this entry in the sources and references list at the end of the page.
Put it into practice
Reading about P21 is the first step — DoseRoutine helps you act on it. These free tools turn what you just learned into a routine.
What interacts with P21?
| Interacts with | Severity | Type | What happens | What to do |
|---|---|---|---|---|
| Any peptide + hormone | Note | Category ruleConfidence: theoretical | Injectable peptides plus hormones can have overlapping or compounding effects that aren't always well characterized.Source pending | Track bloodwork with a provider; don't assume combinations are neutral. |
Frequently asked questions about P21
P21, also known as P021 CNTF mimetic, is a synthetic peptide that scientists are investigating for its potential neurotrophic and neuroprotective effects. It is designed to mimic some of the biological actions of ciliary neurotrophic factor (CNTF), a naturally occurring protein involved in neuronal survival and differentiation.
P21 is thought to act as a mimetic of CNTF, engaging similar or related cellular signaling pathways, primarily the JAK/STAT pathway. This activation is hypothesized to promote neuronal survival, enhance plasticity, and protect neurons from damage, though the precise mechanisms are still under active investigation.
Preclinical research suggests P21 may offer neuroprotection, potentially improve cognitive functions like learning and memory, and promote neuronal plasticity. These areas are being explored for their relevance in supporting overall brain health and in models of neurological conditions.
As a research compound, comprehensive human clinical data on side effects and safety is extremely limited. Most information comes from preclinical studies. Therefore, its use carries significant unknown risks. It is not approved for human use, and self-administration is strongly discouraged. Consult a qualified clinician for any health concerns or before considering any compound.
The scientific understanding of P21 largely originates from in vitro (cell culture) and in vivo (animal) studies published in scientific journals and documented by organizations like PubChem and Examine.com. There is no significant human clinical trial data available.
P21 is a peptide, and interactions are possible with prescriptions, hormones, peptides and other supplements in the same routine. Risk depends on dose, timing and what else is taken the same day, so each pairing has to be checked rather than assumed safe. The free checker at https://doseroutine.com/interaction-checker covers P21 with no sign-up.
Ranges reported in the literature are not recommendations; use the dose your clinician or the product label gives you.
Combining a peptide like P21 with TRT is usually a question of labs rather than a blanket yes or no: the ester, injection interval and any aromatase inhibitor all change the answer. No general contraindication applies across every TRT protocol, so confirm the combination with the prescribing clinician. See the free TRT interaction reference: https://doseroutine.com/trt-supplement-interactions
Each peptide class carries its own profile against P21: a healing peptide raises different questions than a GLP-1 agonist or a growth-hormone secretagogue. Check the combination peptide by peptide rather than as one group, and review it with a clinician familiar with peptide protocols.
Published frequency for P21 varies by protocol and formulation, so the label or prescription is what sets it. Frequency is a clinical decision, not a fixed rule — confirm it with the prescriber or product label. Comparison of apps that keep a schedule like this: https://doseroutine.com/best-dose-tracking-apps
The effect of a missed dose of P21 depends on the protocol and formulation you are on. Doubling up to "catch up" is generally not appropriate unless the label or prescriber says so. Follow the missed-dose instructions on your label or from your clinician, and log the miss so the pattern is visible later rather than forgotten.
For P21 the useful record is the dose, the time it was actually taken, and what else was taken in the same window. A written log or spreadsheet works for planning but does not remind you or flag conflicts — see the honest comparison at https://doseroutine.com/vs/spreadsheet and the wider roundup at https://doseroutine.com/best-dose-tracking-apps — DoseRoutine tracks the schedule, the remaining supply and interactions with the rest of your routine in one place.
60–200 nmol/g of diet in the transgenic-mouse feeding studies. Route reported: Oral, mixed into feed in the cited rodent studies. Frequency reported: Chronic daily dietary administration in the cited studies. These are amounts documented in the cited studies and labels for P21 — they are reported for reference, not a recommendation. Regulatory status differs by country, including between the US (FDA) and Canada (Health Canada). Confirm any amount with a licensed clinician before you take it.
Which studies looked at P21?
Peer-reviewed research indexed in PubMed. Each entry links to the original record.
- 1.The role of p21 in cellular senescence and aging-related diseases(opens PubMed in a new tab)Mol Cells · 2024 · PMID 39304134 · https://pubmed.ncbi.nlm.nih.gov/39304134/
- 2.Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage(opens PubMed in a new tab)DNA Repair (Amst) · 2016 · PMID 27156098 · https://pubmed.ncbi.nlm.nih.gov/27156098/
Sources cited on this page
Specific documents referenced by the numbered markers above. Each number matches the marker in the text.
- PubChem CID 14191208(opens in a new tab)National Center for Biotechnology Information · pubchem.ncbi.nlm.nih.gov/compound/14191208
Verify at
Publisher search links for P21. These are places to check the information — they are not citations, so they are not numbered.
- DrugBank(publisher search, opens in a new tab)DrugBank Online · publisher search
- Examine.com(publisher search, opens in a new tab)Examine.com · publisher search
- NIH Office of Dietary Supplements(publisher search, opens in a new tab)National Institutes of Health · publisher search
- PubMed literature search(publisher search, opens in a new tab)National Library of Medicine · publisher search
- DailyMed labeling archive(publisher search, opens in a new tab)U.S. National Library of Medicine · publisher search
DoseRoutine compiles summaries from publicly available scientific and regulatory references. Always verify important decisions with a licensed clinician. How we source and review this information.
What is the short answer on P21?
Plain-text summary, safe to quote verbatim:
P21, also known by its alias P021 CNTF mimetic, is a synthetic peptide that has garnered attention in the scientific community for its potential neurotrophic and neuroprotective properties. Research on P21 focuses on cognition and mood. Dose, response, and interaction risk vary by individual, so use should be reviewed with a clinician.
Source: DoseRoutine — https://doseroutine.com/library/p21
P21 cheat sheet
DoseRoutine cheat sheet · Peptide
P21
P21, also known by its alias P021 CNTF mimetic, is a synthetic peptide that has garnered attention in the scientific community for its potential neurotrophic and neuroprotective properties.
Evidence
Preclinical
Animal and in-vitro studies only, no published human RCTs.
Studied range
60–200 nmol/g of diet in the transgenic-mouse feeding studies
Route
Oral, mixed into feed in the cited rodent studies
Frequency studied
Chronic daily dietary administration in the cited studies
Research chemicalNo published human trial; evidence is limited to rodent modelsSold as a research chemical, not reviewed by any regulatorBrain
Key references
- Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease (2014)
- Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer's-like memory deficits in the Ts65Dn mouse model of Down syndrome (2017)
Studied ranges, not dosing advice. Not medical advice — talk to a clinician. doseroutine.com/library/p21
Cite this page
Using this in an article, AI answer, or research note? Please attribute:
DoseRoutine. (2026). P21 — Overview, Benefits & Side Effects. Retrieved from https://doseroutine.com/library/p21
What compounds are similar to P21?
Others in the peptide category or studied for the same goals.
Which goals is P21 used for?
Other compounds studied for the same benefits as P21.
Continue exploring
See every compound DoseRoutine catalogs for these goals.